Verrica Pharmaceuticals VRCA

NASDAQ VRCA

$5.06 -0.20 (-3.80%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap109.29 Mn

P/E-3.48

P/S3.60

Div. Yield0.00

Revenue Growth (1y) (Qtr)-53.85

Add ratio to table…

About

Verrica Pharmaceuticals Inc. is a therapeutics company focused on developing and commercializing medications for dermatologic diseases. The firm's lead product YCANTH is a topical treatment for molluscum contagiosum. The company also advances product candidates for common warts and basal cell carcinoma. It operates in the specialty pharmaceutical sector targeting skin conditions. Verrica generates revenue primarily from sales of its approved product YCANTH in the United…

Investment Thesis

▲ Bull case

Verrica Pharmaceuticals (VRCA) demonstrates significant upside potential due to the accelerating commercial traction of YCANTH in the U.S., which saw a 25.4% year-over-year increase in product revenue to $4.3 million and a 51.3% surge in dispensed applicator units to 15,302 in Q1 2026, signaling strong underlying demand that is outpacing revenue growth due to the success of the YCANTH Rx non-dispensing pharmacy platform launched in Q4 2025, which is improving prescription fulfillment and expanding access beyond early adopter dermatologists into pediatricians and physician extenders, thereby unlocking a larger portion of the total addressable market currently estimated at 85% coverage with plans to staff approximately 50 sales representatives to optimize reach and frequency, a move that could meaningfully increase conversion rates as the company shifts from awareness-building to targeted execution in high-potential regions.
The international expansion of YCANTH presents a material near-term catalyst that management underemphasized during the call, particularly the commercial launch in Japan by Torii Pharmaceutical in February 2026, which is generating commercial supply revenue that directly offsets Verrica’s share of common warts clinical trial costs under the 50-50 cost-sharing agreement where Torii funds the first $40 million (~90% of the current budget), thereby reducing net pipeline expenditures and preserving cash reserves, while the positive feedback from the EU’s Committee for Medicinal Products for Human Use confirms no further Phase III trials are needed for marketing authorization, positioning Verrica to advance submission in a large underserved market with the potential for partnership-driven commercialization that could yield royalties and milestones without significant incremental investment.
VP-315 represents a hidden multi-billion-dollar opportunity that the market is overlooking, as Phase II data showed a 97% objective response rate and 86% mean reduction in tumor size for basal cell carcinoma, with more than half of lesions achieving complete histological resolution, and emerging abscopal-like effects suggesting systemic activity that could differentiate the drug in neoadjuvant or multi-lesion settings, supported by market research indicating strong patient and clinician preference for VP-315 as a first-line option over surgical alternatives, which positions it to capture share in a sizable indication where current standards involve invasive procedures with scarring and morbidity, and Verrica’s retention of 100% global commercial rights outside Japan allows for flexible partnership structures to fund Phase III development while maintaining upside potential.

Verrica Pharmaceuticals (VRCA) demonstrates significant upside potential due to the accelerating commercial traction of YCANTH in the U.S., which saw a 25.4% year-over-year increase in product revenue to $4.3 million and a 51.3% surge in dispensed applicator units to 15,302 in Q1 2026, signaling strong underlying demand that is outpacing revenue growth due to the success of the YCANTH Rx non-dispensing pharmacy platform launched in Q4 2025, which is improving prescription fulfillment and expanding access beyond early adopter dermatologists into pediatricians and physician extenders, thereby unlocking a larger portion of the total addressable market currently estimated at 85% coverage with plans to staff approximately 50 sales representatives to optimize reach and frequency, a move that could meaningfully increase conversion rates as the company shifts from awareness-building to targeted execution in high-potential regions.
The international expansion of YCANTH presents a material near-term catalyst that management underemphasized during the call, particularly the commercial launch in Japan by Torii Pharmaceutical in February 2026, which is generating commercial supply revenue that directly offsets Verrica’s share of common warts clinical trial costs under the 50-50 cost-sharing agreement where Torii funds the first $40 million (~90% of the current budget), thereby reducing net pipeline expenditures and preserving cash reserves, while the positive feedback from the EU’s Committee for Medicinal Products for Human Use confirms no further Phase III trials are needed for marketing authorization, positioning Verrica to advance submission in a large underserved market with the potential for partnership-driven commercialization that could yield royalties and milestones without significant incremental investment.
VP-315 represents a hidden multi-billion-dollar opportunity that the market is overlooking, as Phase II data showed a 97% objective response rate and 86% mean reduction in tumor size for basal cell carcinoma, with more than half of lesions achieving complete histological resolution, and emerging abscopal-like effects suggesting systemic activity that could differentiate the drug in neoadjuvant or multi-lesion settings, supported by market research indicating strong patient and clinician preference for VP-315 as a first-line option over surgical alternatives, which positions it to capture share in a sizable indication where current standards involve invasive procedures with scarring and morbidity, and Verrica’s retention of 100% global commercial rights outside Japan allows for flexible partnership structures to fund Phase III development while maintaining upside potential.

▼ Bear case

Verrica Pharmaceuticals (VRCA) faces significant near-term financial pressure despite management’s assertion of cash runway into Q1 2027, as the company reported a GAAP net loss of $9.7 million in Q1 2026 with R&D expenses increasing $1.5 million year-over-year to $3.9 million due to heightened spending on the common warts program and SG&A rising $1.3 million to $10 million from sales force expansion, creating a cash burn trajectory that, if sustained, would deplete the $20.6 million cash balance in under two years, especially given the absence of profitability and the reliance on future milestone payments from Torii that remain contingent on Japanese sales performance, which has not yet been quantified and may not materialize at scale sufficient to meaningfully offset U.S. operating losses.
The growth in YCANTH dispensed applicator units, while impressive at 51.3% year-over-year, may not translate to sustainable revenue expansion, as gross product margin declined slightly to 87.3% from 87.6% in the prior year period, signaling potential pricing pressure or rising cost of goods sold, and the company’s reliance on co-pay assistance programs to drive access introduces variability in gross-to-net adjustments that could erode net revenue per unit, particularly as the annual reset of insurance deductibles in Q1 historically impacts early-year demand, a headwind management acknowledged but did not fully mitigate, raising concerns about the durability of sequential growth beyond the spring and summer months when seasonal demand typically wanes.
Regulatory and commercial progress in Europe, while framed positively, carries substantial execution risk that management did not adequately address, as the confirmation from the Committee for Medicinal Products for Human Use only supports proceeding with a marketing authorization application without additional Phase III trials, yet critical steps such as securing pediatric investigation waivers, determining country-specific pricing and reimbursement strategies, and identifying commercial partners remain unresolved, and the company’s plan to evaluate broad EU access ignores the likelihood of fragmented national formularies and reference pricing mechanisms that could delay launch and compress pricing, especially in cost-conscious markets where molluscum is often managed conservatively, thereby delaying revenue recognition and increasing the burden on Verrica to fund early commercialization efforts without guaranteed returns.

Verrica Pharmaceuticals (VRCA) faces significant near-term financial pressure despite management’s assertion of cash runway into Q1 2027, as the company reported a GAAP net loss of $9.7 million in Q1 2026 with R&D expenses increasing $1.5 million year-over-year to $3.9 million due to heightened spending on the common warts program and SG&A rising $1.3 million to $10 million from sales force expansion, creating a cash burn trajectory that, if sustained, would deplete the $20.6 million cash balance in under two years, especially given the absence of profitability and the reliance on future milestone payments from Torii that remain contingent on Japanese sales performance, which has not yet been quantified and may not materialize at scale sufficient to meaningfully offset U.S. operating losses.
The growth in YCANTH dispensed applicator units, while impressive at 51.3% year-over-year, may not translate to sustainable revenue expansion, as gross product margin declined slightly to 87.3% from 87.6% in the prior year period, signaling potential pricing pressure or rising cost of goods sold, and the company’s reliance on co-pay assistance programs to drive access introduces variability in gross-to-net adjustments that could erode net revenue per unit, particularly as the annual reset of insurance deductibles in Q1 historically impacts early-year demand, a headwind management acknowledged but did not fully mitigate, raising concerns about the durability of sequential growth beyond the spring and summer months when seasonal demand typically wanes.
Regulatory and commercial progress in Europe, while framed positively, carries substantial execution risk that management did not adequately address, as the confirmation from the Committee for Medicinal Products for Human Use only supports proceeding with a marketing authorization application without additional Phase III trials, yet critical steps such as securing pediatric investigation waivers, determining country-specific pricing and reimbursement strategies, and identifying commercial partners remain unresolved, and the company’s plan to evaluate broad EU access ignores the likelihood of fragmented national formularies and reference pricing mechanisms that could delay launch and compress pricing, especially in cost-conscious markets where molluscum is often managed conservatively, thereby delaying revenue recognition and increasing the burden on Verrica to fund early commercialization efforts without guaranteed returns.

Statement Business Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	643.26 Bn	30.58	6.57	60.73 Bn
2	ABBV	AbbVie Inc.	primary	443.31 Bn	70.19	6.89	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	364.74 Bn	115.10	5.48	53.91 Bn
4	NVS	Novartis Ag	primary	266.46 Bn	9.25	3.88	9.59 Bn
5	PFE	Pfizer Inc	primary	158.57 Bn	36.30	2.49	63.19 Bn
6	SNY	Sanofi	primary	52.33 Bn	11.23	0.98	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	43.79 Bn	-24.76	-	-
8	INCY	Incyte Corp	primary	25.23 Bn	15.65	4.34	0.04 Bn

Verrica Pharmaceuticals VRCA

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Statement Business Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password